News & Updates
Filter by Specialty:

Intranasal neuroEPO slows Alzheimer’s progression
An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.
Intranasal neuroEPO slows Alzheimer’s progression
04 Jan 2024
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
In the treatment of patients with acute ischaemic stroke, treatment with exenatide does not appear to have any beneficial effect on neurological function at 7 days but is safe and substantially decreases the frequency of hyperglycaemic events, without leading to hypoglycaemia, according to the results of the phase II TEXAIS trial.
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
12 Dec 2023
Transcranial direct current stimulation improves social functioning in autism spectrum disorder
A double-blind, sham-controlled study by researchers from the Hong Kong Polytechnic University shows that cathodal transcranial direct current stimulation (tDCS) of the left dorsolateral prefrontal cortex (dlPFC) paired with cognitive remediation is a feasible and effective treatment for improving social functioning and information processing in adolescents and young adults with autism spectrum disorder (ASD) who have average to borderline IQ.